Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211538 | 1.00 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL4731613 | 1.00 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL16622532 | 1.00 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL13707743 | 0.89 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL21146168 | 0.89 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL8295708 | 0.89 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL12993554 | 0.89 | CTSK (0.53) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL13211537 | 0.88 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL13232075 | 0.88 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2MAPT | |
| SCHEMBL30695638 | 0.88 | CTSK (0.52) | CTSKCTSSGABRB1GABRB2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8658825-B2 | Method for the preparation of aminophosphine ligands and their use in metal catalysts | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2014-02-25 | — | — | US | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2012-02-02 | — | — | US | disclosed |
| WO-2012013716-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2012-02-02 | — | — | WO | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| WO-2011067306-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | CTSK 1109/4885CTSS 1179/4885GABRB1 1197/4885 |
| US-20120028969-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | CTSK 1109/4885CTSS 1179/4885GABRB1 1197/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | CTSK 839/4885CTSS 587/4885GABRB1 1126/4885 |
| US-20100204514-A1 | METHOD FOR THE PREPARATION OF AMINOPHOSPHINE LIGANDS AND THEIR USE IN METAL CATALYSTS | PNISR, PRMT9, PRMT8 | CTSK 4009/4885CTSS 4326/4885GABRB1 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.